<DOC>
	<DOCNO>NCT02179359</DOCNO>
	<brief_summary>This study collect outcome stem cell transplantation patient hematologic disease cancer .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplant High Risk Hemoglobinopathies</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Lipomatosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Diagnosis Sickle Cell Disease , Thalassemia , Diamond Blackfan Anemia nonmalignant hematologic disorder stem cell transplant indicate Acceptable stem cell source identify Performance status ≥ 70 % ( Karnofsky ) , ≥ 70 ( Lansky play score ) Creatinine &lt; 2.0 mg/dl adult glomerular filtration rate &gt; 50 ml/min child Bilirubin , Aspartate Aminotransferase , Alkaline phosphatase &lt; 5 time upper limit institutional normal Absence decompensated congestive heart failure , uncontrolled arrhythmia leave ventricular ejection fraction &gt; 40 % active , uncontrolled infection pregnant breastfeeding HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stem Cell Transplant</keyword>
</DOC>